跳至主要内容
临床试验/NCT04883827
NCT04883827已完成不适用

Monitoring Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer

Vanderbilt-Ingram Cancer Center3 个研究点 分布在 1 个国家目标入组 180 人开始时间: 2021年1月6日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
180
试验地点
3
主要终点
Evaluate tumor cfDNA as a dynamic marker of response to IO therapy

研究概览

简要总结

This study will assess whether DNA released by kidney cancer into the blood stream and urine of patients can be used to monitor tumor burden and tumor response to treatment in patients receiving immunotherapy

详细描述

Primary Objective:

  • Evaluate tumor cell free (cf)DNA as a dynamic marker of response to immuno-oncology (IO) therapy

Exploratory Objective:

  • Collect data on somatic mutations in cfDNA to gain insight into the biology of IO-responders and -non-responders

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Renal Cell Carcinoma with clear cell component
  • Receiving IO-containing regimen
  • Measurable disease per RECIST 1.1

排除标准

  • Active cancer (exclusion criteria only for healthy patient cohort)

结局指标

主要结局

Evaluate tumor cfDNA as a dynamic marker of response to IO therapy

时间窗: Up to about 2 years

Measure of changes in the amount of tumor DNA correlated with result of routine tumor imaging studies

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Scott Haake, MD

Principal Investigator

Vanderbilt-Ingram Cancer Center

研究点 (3)

Loading locations...

相似试验